Global Alzheimer’s Platform Foundation Statement on FDA Accelerated Approval of Lecanemab

“With this approval, it is incumbent on Center for Medicare and Medicaid Services (CMS) Administrator Chiquita Brooks-LaSure and the drug’s sponsors to offer this life-changing therapy to patients quickly, while prioritizing access and economic fairness.” Statement attributed to Global Alzheimer’s Platform Foundation President John Dwyer: Washington, D.C. (Jan. 6, 2023) — We applaud the Food […]

Read More…

Global Alzheimer’s Platform Foundation (GAP) Hopeful With ARPA-H Appropriations

Washington, DC — December 23, 2022–Appropriations bills are not simply about funding. They are about people. That is why we are grateful that Congress prioritized funding for accelerated and disruptive Alzheimer’s disease research in the 2023 Omnibus Appropriations Bill. Increases in funding for the Advanced Research Projects Agency for Health (ARPA-H) and the National Institutes […]

Read More…

ICER Fails People with Alzheimer’s Disease, The Global Alzheimer’s Platform Foundation Calls On Allies to Debunk Report

Washington, DC — December 23, 2022–The Institute for Clinical and Economic Review (ICER) has again failed in its attempt to value the benefit provided by a new, life-improving Alzheimer’s treatment, threatening millions of Americans who are living with Alzheimer’s disease. The report, “Beta-Amyloid Antibodies for Early Alzheimer’s Disease,” released yesterday, advances an analytical framework that […]

Read More…

GAP President John Dwyer, on Lecanemab detailed results: “There is every reason for the Alzheimer’s community to have optimism today”

Washington, D.C. (Nov. 30, 2022) – “Following the positive, detailed results from Eisai on lecanemab, a monoclonal antibody therapy for the treatment of Alzheimer’s, there is every reason for the Alzheimer’s community to have optimism today. Thanks to the unwavering commitment of Eisai, its clinical trial partners, and most importantly, the people who participated in […]

Read More…

First of its Kind Head-to-Head Study Comparing Leading Biomarkers for Detecting Alzheimer’s Disease Closes With Unprecedented Representation from Underrepresented Populations

The Global Alzheimer’s Platform Foundation (GAP) closed its ground-breaking blood-based and digital biomarker platform study, Bio-Hermes, which is powered to measure more than 36 technologies’ effectiveness across three stages of Alzheimer’s disease, while drawing from all races and ethnic groups affected by the disease. WASHINGTON, DC (Nov. 15, 2022) — In 18 months, the Global […]

Read More…

Statement on Roche Announcement on Gantenerumab Attributed to John Dwyer, GAP Foundation President

The Global Alzheimer’s Platform Foundation (GAP) is grateful for Roche’s efforts and leadership on the gantenerumab study to treat Alzheimer’s disease. We applaud Roche’s robust and well-designed study, and for holding to an ongoing commitment to research in this field. Every clinical study improves our understanding of Alzheimer’s disease, so this data will be of […]

Read More…

Global Alzheimer’s Platform Foundation (GAP) Supports New Bill from U.S. Representative Vern Buchanan

WASHINGTON, DC, Oct. 5, 2022 — Today, the Global Alzheimer’s Platform Foundation (GAP) applauds and vigorously supports Congressmembers Vern Buchanan (R-FL) and Nanette Diaz Barragán (D-CA) for bringing forward a new bill to help ensure coverage of potentially life-saving drugs and new treatments for Medicare beneficiaries, including access to approved Alzheimer’s treatments. The bill — known as […]

Read More…

Global Alzheimer’s Platform Foundation (GAP) Celebrates Lecanemab’s Positive Clinical Trial Results

WASHINGTON, DC, Sept. 28, 2022 — Today, the Global Alzheimer’s Platform Foundation (GAP) applauds and welcomes the Phase 3 study results on lecanemab for treating Alzheimer’s disease, marking an enormous milestone for millions of people living with Alzheimer’s disease. The positive trial results, released by Eisai Tuesday night, show that the novel drug helped slow cognitive decline […]

Read More…

South Texas Health Clinic Applauded for Advancing Diverse Representation in Alzheimer’s Clinical Trials, Surmounting Challenges

GAP-Net Site El Faro Health and Therapeutics in Texas’ Starr County continues working to connect the area’s predominantly Hispanic community with access to Alzheimer’s research and health care. Washington, D.C. — Today, Global Alzheimer’s Platform Foundation (GAP) John Dwyer applauded the work that Dr. James Falcon and the whole El Faro Health and Therapeutics team […]

Read More…